| Total population (n = 798) | Without event (n = 618) | With event (n = 180) | P value |
---|---|---|---|---|
Age, years | 60.9 ± 8.3 | 60.3 ± 8.1 | 62.9 ± 8.6 | < 0.001 |
Sex, male, n (%) | 545 (68.3) | 430 (69.6) | 115 (63.9) | 0.149 |
BMI, kg/m2 | 26.7 ± 3.2 | 26.7 ± 3.2 | 26.6 ± 3.2 | 0.772 |
Heart rate, bpm | 71.7 ± 10.2 | 71.5 ± 9.8 | 72.1 ± 11.4 | 0.502 |
SBP, mmHg | 131.8 ± 17.1 | 130.8 ± 16.3 | 135.1 ± 19.5 | 0.007 |
DBP, mmHg | 76.8 ± 10.1 | 76.4 ± 9.8 | 78.1 ± 11.1 | 0.052 |
Smoking, n (%) | 417 (52.3) | 332 (53.7) | 85 (47.2) | 0.124 |
Drinking, n (%) | 184 (23.1) | 149 (24.1) | 35 (19.4) | 0.191 |
Family history of CAD, n (%) | 93 (11.7) | 73 (11.8) | 20 (11.1) | 0.796 |
Duration of diabetes, years | 8.2 ± 4.3 | 8.0 ± 4.1 | 9.1 ± 4.7 | 0.007 |
Medical history, n (%) | ||||
 Hypertension | 573 (71.8) | 449 (72.7) | 124 (68.9) | 0.323 |
 Dyslipidemia | 710 (89.0) | 537 (86.9) | 173 (96.1) | 0.001 |
 Prior MI | 175 (21.9) | 118 (19.1) | 57 (31.7) | < 0.001 |
 Prior PCI | 151 (18.9) | 106 (17.2) | 45 (25.0) | 0.018 |
 Prior stroke | 109 (13.7) | 80 (12.9) | 29 (16.1) | 0.276 |
 Prior PVD | 125 (15.7) | 93 (15.0) | 32 (17.8) | 0.375 |
Laboratory results | ||||
 TGs, mg/dL | 138.2 (97.2, 198.5) | 127.6 (91.3, 174.8) | 209.1 (134.9, 299.5) | < 0.001 |
 TC, mg/dL | 157.2 ± 39.7 | 153.5 ± 39.4 | 170.2 ± 38.2 | < 0.001 |
 LDL-C, mg/dL | 94.2 ± 33.1 | 93.2 ± 33.9 | 97.6 ± 29.8 | 0.112 |
 HDL-C, mg/dL | 36.9 ± 8.7 | 37.3 ± 8.8 | 35.3 ± 8.0 | 0.005 |
 hs-CRP, mg/L | 1.6 (0.7, 4.1) | 1.5 (0.6, 3.9) | 2.0 (0.9, 4.4) | 0.011 |
 Creatinine, mg/dL | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.384 |
 eGFR, mL/(min * 1.73 m2) | 96.5 ± 21.6 | 97.4 ± 21.7 | 93.5 ± 21.1 | 0.030 |
 Uric acid, μmol/L | 328.0 ± 75.6 | 328.3 ± 75.3 | 327.0 ± 76.6 | 0.842 |
 FBG, mg/dL | 127.7 (109.6, 157.0) | 125.3 (108.1, 148.4) | 141.5 (118.4, 173.3) | < 0.001 |
 HbA1c, % | 7.5 ± 1.3 | 7.3 ± 1.2 | 8.0 ± 1.3 | < 0.001 |
 TyG index | 9.1 ± 0.6 | 9.0 ± 0.6 | 9.6 ± 0.7 | < 0.001 |
 LVEF, % | 64.0 ± 6.6 | 64.3 ± 6.3 | 62.7 ± 7.5 | 0.010 |
Initial diagnosis, n (%) | 0.149 | |||
 UA | 650 (81.5) | 510 (82.5) | 140 (77.8) |  |
 NSTEMI | 148 (18.5) | 108 (17.5) | 40 (22.2) |  |
Pre-admission medication, n (%) | ||||
 ACEI | 79 (9.9) | 62 (10.0) | 17 (9.4) | 0.816 |
 ARB | 128 (16.0) | 99 (16.0) | 29 (16.1) | 0.976 |
 DAPT | 253 (31.7) | 194 (31.4) | 59 (32.8) | 0.725 |
 Aspirin | 427 (53.5) | 325 (52.6) | 102 (56.7) | 0.334 |
 Clopidogrel | 264 (33.1) | 203 (32.8) | 61 (33.9) | 0.794 |
 β-blocker | 166 (20.8) | 127 (20.6) | 39 (21.7) | 0.745 |
 Statins | 233 (29.2) | 190 (30.7) | 43 (23.9) | 0.075 |
 Proton pump inhibitor | 8 (1.0) | 7 (1.1) | 1 (0.6) | 0.796 |
 Oral hypoglycemic agents | 413 (51.8) | 324 (52.4) | 89 (49.4) | 0.481 |
 Metformin | 170 (21.3) | 138 (22.3) | 32 (17.8) | 0.189 |
 Alpha-glucosidase inhibitor | 185 (23.2) | 140 (22.7) | 45 (25.0) | 0.512 |
 Sulfonylurea | 126 (15.8) | 102 (16.5) | 24 (13.3) | 0.304 |
 Dipeptidyl peptidase 4 inhibitor | 15 (1.9) | 12 (1.9) | 3 (1.7) | 0.811 |
 Insulin | 225 (28.2) | 163 (26.4) | 62 (34.4) | 0.034 |
Post-discharge medication, n (%) | ||||
 ACEI | 234 (29.3) | 177 (28.6) | 57 (31.7) | 0.433 |
 ARB | 384 (48.1) | 294 (47.6) | 90 (50.0) | 0.566 |
 DAPT | 796 (99.7) | 617 (99.8) | 179 (99.4) | 0.934 |
 DAPT interruption in 12 months | 12 (1.5) | 9 (1.5) | 3 (1.7) | 0.838 |
 Aspirin | 797 (99.9) | 617 (99.8) | 180 (100.0) | 0.589 |
 Clopidogrel | 797 (99.9) | 618 (100.0) | 179 (99.4) | 0.226 |
 β-blocker | 744 (93.2) | 579 (93.7) | 165 (91.7) | 0.342 |
 Statins | 787 (98.6) | 611 (98.9) | 176 (97.8) | 0.459 |
 Statins interruption in 12 months | 31 (3.9) | 21 (3.4) | 10 (5.6) | 0.187 |
 Proton pump inhibitor | 790 (99.0) | 613 (99.2) | 177 (98.3) | 0.554 |
 Oral hypoglycemic agents | 409 (51.3) | 321 (51.9) | 88 (48.9) | 0.471 |
 Metformin | 167 (20.9) | 135 (21.8) | 32 (17.8) | 0.238 |
 Alpha-glucosidase inhibitor | 181 (22.7) | 137 (22.2) | 44 (24.4) | 0.521 |
 Sulfonylurea | 123 (15.4) | 99 (16.0) | 24 (13.3) | 0.380 |
 Dipeptidyl peptidase 4 inhibitor | 15 (1.9) | 12 (1.9) | 3 (1.7) | 0.811 |
 Insulin | 217 (27.2) | 156 (25.2) | 61 (33.9) | 0.022 |
Angiographic data | ||||
 LM disease, n (%) | 44 (5.5) | 22 (3.6) | 22 (12.2) | < 0.001 |
 One-vessel disease, n (%) | 167 (20.9) | 146 (23.6) | 21 (11.7) | 0.001 |
 Two-vessel disease, n (%) | 287 (36.0) | 233 (37.7) | 54 (30.0) | 0.058 |
 Three-vessel disease, n (%) | 344 (43.1) | 239 (38.7) | 105 (58.3) | < 0.001 |
 Chronic total occlusion, n (%) | 117 (14.7) | 67 (10.8) | 50 (27.8) | < 0.001 |
 Diffuse lesion, n (%) | 237 (29.7) | 169 (27.3) | 68 (37.8) | 0.007 |
 Bifurcation lesion, n (%) | 186 (23.3) | 124 (20.1) | 62 (34.4) | < 0.001 |
 In-stent restenosis, n (%) | 58 (7.3) | 38 (6.1) | 20 (11.1) | 0.024 |
 SYNTAX score | 12.0 ± 5.5 | 11.1 ± 5.1 | 15.2 ± 6.0 | < 0.001 |
Procedural results | ||||
 Target vessel territory, n (%) | ||||
  LM | 25 (3.1) | 14 (2.3) | 11 (6.1) | 0.009 |
  LAD | 513 (64.3) | 393 (63.6) | 120 (66.7) | 0.449 |
  LCX | 335 (42.0) | 249 (40.3) | 86 (47.8) | 0.073 |
  RCA | 398 (49.9) | 300 (48.5) | 98 (54.4) | 0.164 |
 DES implantation, n (%) | 785 (98.4) | 608 (98.4) | 177 (98.3) | 0.964 |
 DCB use, n (%) | 15 (1.9) | 10 (1.6) | 5 (2.8) | 0.313 |
 Complete revascularization, n (%) | 414 (51.9) | 333 (53.9) | 81 (45.0) | 0.036 |
 Number of stents | 2.1 ± 1.3 | 2.0 ± 1.2 | 2.4 ± 1.5 | 0.001 |